JP2010522699A5 - - Google Patents

Download PDF

Info

Publication number
JP2010522699A5
JP2010522699A5 JP2010500039A JP2010500039A JP2010522699A5 JP 2010522699 A5 JP2010522699 A5 JP 2010522699A5 JP 2010500039 A JP2010500039 A JP 2010500039A JP 2010500039 A JP2010500039 A JP 2010500039A JP 2010522699 A5 JP2010522699 A5 JP 2010522699A5
Authority
JP
Japan
Prior art keywords
scoliosis
opn
subject
expression
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010500039A
Other languages
English (en)
Japanese (ja)
Other versions
JP5426530B2 (ja
JP2010522699A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2008/000595 external-priority patent/WO2008119170A1/en
Publication of JP2010522699A publication Critical patent/JP2010522699A/ja
Publication of JP2010522699A5 publication Critical patent/JP2010522699A5/ja
Application granted granted Critical
Publication of JP5426530B2 publication Critical patent/JP5426530B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010500039A 2007-03-30 2008-03-31 脊柱側弯症の危険性の決定方法 Expired - Fee Related JP5426530B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US90940807P 2007-03-30 2007-03-30
US60/909,408 2007-03-30
US2557108P 2008-02-01 2008-02-01
US61/025,571 2008-02-01
PCT/CA2008/000595 WO2008119170A1 (en) 2007-03-30 2008-03-31 Method of determining risk of scoliosis

Publications (3)

Publication Number Publication Date
JP2010522699A JP2010522699A (ja) 2010-07-08
JP2010522699A5 true JP2010522699A5 (enExample) 2011-04-28
JP5426530B2 JP5426530B2 (ja) 2014-02-26

Family

ID=39807753

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010500039A Expired - Fee Related JP5426530B2 (ja) 2007-03-30 2008-03-31 脊柱側弯症の危険性の決定方法

Country Status (10)

Country Link
US (3) US20100075333A1 (enExample)
EP (1) EP2132568B1 (enExample)
JP (1) JP5426530B2 (enExample)
KR (1) KR101436578B1 (enExample)
CN (1) CN101680887B (enExample)
AU (1) AU2008234374B2 (enExample)
CA (1) CA2682114C (enExample)
IL (1) IL201186A (enExample)
MX (1) MX2009010400A (enExample)
WO (1) WO2008119170A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012045176A1 (en) * 2010-10-04 2012-04-12 Chu Sainte-Justine Biomechanical-based methods of diagnosing scoliosis
DE102012102338A1 (de) 2012-03-20 2013-09-26 Hauni Maschinenbau Ag Messanordnung zum Messen von in Strangmaschinen der Tabak verarbeitenden Industrie hergestellten und geförderten Strängen
US20150038511A1 (en) 2012-08-09 2015-02-05 Celgene Corporation Treatment of immune-related and inflammatory diseases
AU2013299625B2 (en) 2012-08-09 2018-02-01 Celgene Corporation Treatment of immune-related and inflammatory diseases
CA2914213A1 (en) 2013-06-17 2014-12-24 Alain Moreau A method of increasing gipcr signalization in the cells of a scoliotic subject
CN105408744B (zh) * 2013-06-17 2019-05-21 圣-贾斯汀大学中心医院 特发性脊柱侧凸的严重进展的新标记物及其用于分层脊柱侧凸患者和预测发展脊柱侧凸的风险的用途
KR20160020552A (ko) 2013-06-17 2016-02-23 슈 생-쥐스땡 척추측만증 및 척추측만증 진행에 대한 마커로서 Gi 단백질 인산화, 척추측만 개체에서 GiPCR 신호전달을 증가시키는 방법
WO2015032005A1 (en) * 2013-09-09 2015-03-12 Chu-Sainte-Justine New marker for the classification, diagnosis and treatment of scoliosis
EP3145513B1 (en) 2014-05-19 2023-11-15 Celgene Corporation 3-(4-((4-(morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus
CN106310610A (zh) * 2016-10-21 2017-01-11 上海交通大学医学院附属新华医院 一种脊柱侧凸特定运动疗法
CN106841593B (zh) * 2017-03-24 2018-08-17 北京致成生物医学科技有限公司 Lacc1和fhl2基因在制备脊柱侧弯检测产品中的应用
CN111638329B (zh) * 2020-06-09 2021-06-01 南方医科大学 一种用于检测布鲁氏菌病elispot检测试剂盒及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
SE9101642D0 (sv) * 1991-05-30 1991-05-30 Kabi Pharmacia Ab Phospholipids
EP0767378A1 (de) * 1993-06-22 1997-04-09 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Verfahren zur Diagnose und Analyse von Magenkarzinomen
EP0778776A1 (en) 1994-08-30 1997-06-18 Hyal Pharmaceutical Corporation Hyaluronic acid and derivatives for modulation of cellular activity
US5858709A (en) * 1996-10-15 1999-01-12 Smithkline Beecham P.L.C. Fibronectin binding protein B compounds
US6025155A (en) * 1996-04-10 2000-02-15 Chromos Molecular Systems, Inc. Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US20020160970A1 (en) * 1996-04-10 2002-10-31 Gyula Hadlaczky Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
WO1998008379A1 (en) 1996-08-27 1998-03-05 Dana-Farber Cancer Institute Methods for identifying modulators of cellular interactions mediated by osteopontin
US6150162A (en) * 1998-12-17 2000-11-21 Isis Pharmaceuticals Inc. Antisense modulation of CD44 expression
JP2005517379A (ja) 1999-01-18 2005-06-16 オステオミーター・ビオテク・エー/エス 遺伝的疾病素因
IL145851A0 (en) * 1999-04-15 2002-07-25 Childrens Medical Center Osteopontin-derived chemotactic and inhivitory agents and uses therefor
DE60131525T2 (de) 2000-03-23 2008-09-25 Glaxo Group Ltd., Greenford Verfahren zum screening von inhibitoren für osteopontin
EP1431310A4 (en) * 2001-09-25 2005-03-23 Immuno Biological Lab Co Ltd ANTI-OSTEOPONTIN RECOMBINANT ANTIBODY AND USE THEREOF
CA2373854A1 (en) 2002-02-28 2003-08-28 Alain Moreau Methods of diagnosing and counteracting adolescent idiopathic scoliosis
WO2003081201A2 (en) * 2002-03-21 2003-10-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Peripheral blood cell markers useful for diagnosing multiple sclerosis and methods and kits utilizing same
US20040110933A1 (en) * 2002-09-13 2004-06-10 Dyax Corporation CD44-binding ligands
US20050282163A1 (en) * 2003-02-03 2005-12-22 Medstar Research Institute Washington Hospital Center Polymorphisms in elastin, fibrillin and related genes as predisposing to restenosis and to a therosclerosis
US20090104620A1 (en) * 2007-07-03 2009-04-23 Axial Biotech, Inc. Simplified Method of Determining Predisposition to Scoliosis

Similar Documents

Publication Publication Date Title
JP2010522699A5 (enExample)
ES2403310T3 (es) Antibiótico para su utilización en una infección local
WO2010038974A3 (ko) 이뮤노글로블린 에이 신증과 티지비엠 신증의 진단용 조성물 및 키트
Qian et al. Increased IL-23 and IL-17 expression by peripheral blood cells of patients with primary biliary cirrhosis
RU2014118584A (ru) Композиции и способы лечения сердечной недостаточности
WO2014059178A1 (en) Differential expression of novel protein markers for the diagnosis and treatment of eosinophilic esophagitis
JP2010516678A5 (enExample)
WO2009132058A3 (en) Levels of bcma protein expression on b cells and use in diagnostic methods
Takač et al. Importance of interleukin 6 in pathogenesis of inflammatory bowel disease
JP2012509477A5 (enExample)
RU2019106324A (ru) Гистоны и/или proadm в качестве маркеров, свидетельствующих о неблагоприятном событии
Stanescu et al. Salivary biomarkers of inflammation in systemic lupus erythematosus
Lien et al. Associations among systemic blood pressure, microalbuminuria and albuminuria in dogs affected with pituitary-and adrenal-dependent hyperadrenocorticism
Yuan et al. High expression of interleukin-33/ST2 predicts the progression and poor prognosis in chronic hepatitis B patients with hepatic flare
RU2008116567A (ru) Биомаркеры
Banaszak et al. Endothelin-1 (ET-1), N-terminal fragment of pro-atrial natriuretic peptide (NTpro-ANP), and tumour necrosis factor alpha (TNF-α) in children with primary hypertension and hypertension of renal origin
JP2012526543A5 (enExample)
Palatini et al. Cystatin C as predictor of microalbuminuria in the early stage of hypertension
Magnussen et al. Safety and tolerability of an oral MMP-9 and-12 inhibitor, AZD1236, in patients with moderate-to-severe COPD: a randomised controlled 6-week trial
Kim et al. Clinical significance of anti-Saccharomyces cerevisiae antibody (ASCA) in Korean patients with Crohn's disease and its relationship to the disease clinical course
Hanibuchi et al. Clinical significance of fractional exhaled nitric oxide and periostin as potential markers to assess therapeutic efficacy in patients with cough variant asthma
JP6934013B2 (ja) 糖尿病性腎症の早期病態の特異的な診断を可能とする検査方法
Kikuchi et al. Urinary and circulating levels of the anti-angiogenic isoform of vascular endothelial growth factor-A in patients with chronic kidney disease
Kim et al. Serum cytokines markers in toluene diisocyanate-induced asthma
Swedin et al. Prostaglandin modulation of airway inflammation and hyperresponsiveness in mice sensitized without adjuvant